Correction to: Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer
Adv Ther
.
2022 Jul;39(7):3423.
doi: 10.1007/s12325-022-02178-2.
Authors
Jesse A Sussell
1
,
Joshua A Roth
2
,
Craig S Meyer
2
,
Anita Fung
3
,
Svenn A Hansen
4
Affiliations
1
Evidence for Access, US Medical Affairs, Genentech, South San Francisco, CA, USA.
[email protected]
.
2
Evidence for Access, US Medical Affairs, Genentech, South San Francisco, CA, USA.
3
US Medical Affairs, Genentech, South San Francisco, CA, USA.
4
F. Hoffmann-La Roche, Basel, Switzerland.
PMID:
35524841
DOI:
10.1007/s12325-022-02178-2
No abstract available
Publication types
Published Erratum